MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2023 International Congress

    Demographic, clinical and genetic factors affecting amantadine response among patients with Parkinson disease

    J. Yu, L. Saadatpour, H. Kaur, I. Mata, H. Fernandez (Cleveland, USA)

    Objective: To identify factors that correlate with efficacy and tolerability of amantadine to predict therapeutic outcomes Background: Amantadine is the only commercially available medication to…
  • 2023 International Congress

    Are GBA–Parkinson Disease patients’ good candidates for Deep Brain Stimulation? A Longitudinal Multicentric study on a Large Italian Cohort

    M. Avenali, R. Zangaglia, G. Cuconato, I. Palmieri, A. Albanese, CA. Artusi, M. Bozzali, F. Cavallieri, R. Cilia, A. Cocco, R. Eleopra, A. Imarisio, G. Imbalzano, C. Ledda, L. Lopiano, M. Malaguti, F. Mameli, P. Mitrotti, F. Spagnolo, C. Tassorelli, F. Valentino, F. Valzania, A. Di Fonzo, C. Pacchetti, EM. Valente (Pavia, Italy)

    Objective: To investigate the impact of GBA variants on the long-term outcome of deep brain stimulation (DBS) in a large cohort of Italian PD subjects…
  • 2023 International Congress

    A single centre retrospective study of dual target deep brain stimulation for clinically complex essential and dystonic tremor – a 5-year follow up

    H. Shepherd, R. Heartshorne, J. Osman-Farah, A. Macerollo (Liverpool, United Kingdom)

    Objective: Measure efficacy of dual target deep brain stimulation in pharmaco-refractory tremors. Background: Tremor is characterised by involuntary rhythmic movement present in one or more…
  • 2023 International Congress

    Pharmacokinetics, Safety and Tolerability of Foslevodopa/Foscarbidopa Following Continuous Subcutaneous Infusion to Arm, Thigh and Flank compared to Abdomen in Parkinson’s Disease Patients

    Y. Han, H. Kalluri, A. Jeong, C. Locke, M. Facheris, S. Gupta, M. Rosebraugh (North Chicago, USA)

    Objective: To characterize safety/tolerability and pharmacokinetics (PK) of levodopa (LD) and carbidopa (CD) after delivery of foslevodopa/foscarbidopa in Parkinson’s disease (PD) patients at 4 different…
  • 2023 International Congress

    Deep brain stimulation and fusion technologies: a synthesis study

    V. Rama Raju (Hyderabad, India)

    Objective: The major thrust is analyzing the large amounts data computationally generated and synthesizing it into useful systems-wide models of biological processes. Background: It is…
  • 2023 International Congress

    Stability and predictability of motor symptom control in patients with advanced Parkinson’s disease (aPD) receiving continuous subcutaneous foslevodopa/foscarbidopa (LDP/CDP)

    R. Pahwa, I. Malaty, M. Soileau, V. Fung, D. Santos Garcia, C. Carroll, T. Henriksen, A. Epstein, C. Yan, A. Alobaidi, A. Shewale, A. Spiegel, M. Facheris, M. Shah, P. Kukreja, J. Zamudio, K. Chaudhuri (Kansas City, USA)

    Objective: To evaluate temporal changes in motor states (OFF and ON without troublesome dyskinesia [TD; good ON]) throughout the waking day in patients with aPD…
  • 2023 International Congress

    Whole exome sequencing of 67 Swedish Parkinson patients identifies a family with VPS35 D620N

    E. Kafantari, A. Puschmann (Lund, Sweden)

    Objective: To determine the usefulness of WES in the diagnostic evaluation of Parkinson’s disease (PD) patients and to set up computational pathways for the identification…
  • 2023 International Congress

    Apomorphine effects on Parkinson’s disease fluctuation related pain: a pilot study

    P. Alizadeh, V. Bruno, K. Naser, A. Abusarair, B. Achen (Calgary, Canada)

    Objective: To evaluate the effect and safety of subcutaneous apomorphine as a treatment for fluctuation-related pain in Parkinson's disease (PD). Background: Pain is one of…
  • 2023 International Congress

    The Blood-Brain Barrier Integrity and Prevalence of Intrathecal T Helper 17.1 Cells in Huntington´s Disease

    B. ásbjörnsdóttir, C. Musaeus, M. Hellem, T. Vinther-Jensen, L. Hjermind, A. Simonsen, M. von Essen, F. Sellebjerg, J. Nielsen (Copenhagen, Denmark)

    Objective: The aim of the study was to investigate the potential role of cerebrospinal fluid (CSF)/plasma albumin quotient (Q-Alb) as a biomarker for blood-brain barrier…
  • 2023 International Congress

    Levodopa-entacapone-carbidopa intestinal gel infusion for Parkinson’s disease: An analysis of data collected from the Swedish national register of Parkinson’s disease.

    M. öthman, P. Odin, F. Bergquist, A. Johansson, R. Constantinescu, M. Scharfenort, H. Widner, D. Nyholm (Uppsala, Sweden)

    Objective: To investigate efficacy, tolerability, and safety of levodopa-entacapone-carbidopa intestinal gel (LECIG) in Parkinson’s disease. Background: LECIG was introduced in 2019. The approval was based…
  • « Previous Page
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • …
  • 186
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley